GLP-1 Weight Loss Drugs Are Getting Cheaper—But Your Total Bill Might Still Rise

Good news and bad news are colliding in the world of weight loss medications. While the cost per prescription for GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) is expected to fall significantly in 2026, the total amount employers and insurers spend on these medications will likely still climb—creating a paradox that's reshaping how healthcare systems approach obesity treatment.

The weight management category has become one of the fastest-growing areas in pharmacy benefits, driven by strong clinical results, expanding treatment options, and broader eligibility criteria. With 30 to 40 percent of U.S. adults meeting obesity criteria by body mass index (BMI), and millions more overweight with cardiometabolic risk factors, demand for these medications shows no signs of slowing.

Why Are GLP-1 Costs Dropping While Total Spending Rises?

The math is straightforward but sobering. CVS Caremark, one of the nation's largest pharmacy benefit managers, projects a 15 percent decrease in net prescription costs for GLP-1 weight loss medications in 2026 compared to 2025 for commercial clients using standard utilization management. This improvement came through product-specific negotiations across injectable and oral formulations, formulary optimization, and strategic contracting. Oral Wegovy, which launched in 2025, came in at a better net cost than expected and at the same price as injectable versions.

Yet despite these per-prescription savings, overall category spending is expected to rise approximately 10 percent for clients maintaining their current benefit designs. The culprit is utilization—more people are using these medications, and they're using them for longer periods. Weight management GLP-1 use is anticipated to grow roughly 25 percent in 2026 alone.

"This is the crux of the challenge: price is improving, but total spend is not. The difference is utilization—and utilization is where strategy matters most," according to industry analysis of the current market landscape.

What's Driving the Explosive Growth in GLP-1 Use?

Several factors are accelerating adoption beyond traditional weight loss seekers. New oral formulations are reducing the intimidation factor associated with injectable medications. Oral Wegovy is already available, and Lilly's orforglipron is expected to launch mid-2026, giving patients more choices. Higher-strength options are also expanding the market—clinical studies show that people taking the higher-strength Wegovy 7.2 milligram dose experienced approximately 21 percent weight loss, meaning patients can now achieve 20 percent or greater body weight loss with either Wegovy or Zepbound.

Clinicians are increasingly viewing GLP-1 therapy as a foundational tool for managing chronic metabolic disease rather than a peripheral benefit. This shift in medical perspective is driving prescriptions across broader patient populations, not just those with severe obesity.

How to Manage GLP-1 Costs Without Sacrificing Outcomes

• Wraparound Support Programs: Integrated care programs that combine pharmacy benefits with clinical oversight, nutrition planning, dietician support, and connected monitoring devices have shown measurable results—clients using comprehensive weight management programs saw up to 42 percent less spending on GLP-1 medications approved for weight loss.
• Utilization Management Strategies: Intentional utilization management coupled with improved net costs can provide budget stability for employers, but only if both elements work together to control total category spending.
• Formulary Optimization: Strategic negotiations across multiple GLP-1 options and careful formulary design can help balance access with cost containment.
• Outcomes Monitoring: Higher-strength formulations require robust outcomes tracking and benefit designs that account for deeper, more durable weight loss trajectories to ensure long-term success.

What Does This Mean for Patients and Employers?

For employers planning 2026 budgets, the improved net-cost environment could provide welcome stability—but only if coupled with intentional utilization management and wraparound support. The conversation in healthcare has shifted from simply ensuring access to GLP-1 medications to ensuring sustainability of these programs long-term.

For patients, the expanding options and lower per-dose costs mean more choices in how to take these medications. The availability of oral formulations alongside injectables, combined with higher-strength options, allows for more personalized treatment approaches. However, the success of these medications depends heavily on sustained use and lifestyle support—which is where comprehensive weight management programs become critical.

As the GLP-1 market continues to evolve in 2026, the real challenge won't be access or even cost per prescription. It will be building sustainable systems that deliver lasting health outcomes while managing the total financial impact on healthcare budgets. The medications are becoming more affordable, but the question of how to use them wisely—and for whom—remains the central puzzle healthcare systems must solve.